Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum

Clin Chim Acta. 2021 Oct:521:59-63. doi: 10.1016/j.cca.2021.06.023. Epub 2021 Jun 18.

Abstract

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL receptors. Inhibition of PCSK9 increase uptake of LDL-particles and pathogen-associated molecular patterns (PAMPs). The aim of our study was to evaluate biological variation of serum PCSK9.

Methods: Within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a 6-week protocol (7 samples, equidistant time intervals). Serum concentration of PCSK9 was measured by a Quantikine ELISA assay (R&D systems, Bio-Techne Ltd., UK) on a DS2 ELISA reader (Dynex Technologies GmbH, Germany). Precision (CVA) was assessed by duplicate measurements. Two methods with different levels of robustness were used for the estimation of CVI, SD-ANOVA and CV-ANOVA method. We calculated the index of individuality and reference change values. The experiment was fully compliant with EFLM database checklist.

Results: The within-subject values of PCSK9 in healthy persons, as calculated by two statistical methods, were 23.2% (SD-ANOVA with CVA of 5.6%) and 26.6% (CV-ANOVA with CVA of 4.8%). The CVG was 10.9% (SD-ANOVA), index of individuality and RCV were 2.13 and 66.3%, respectively.

Conclusions: The high index of individuality indicates that common reference intervals can be used to interpret serum PSCK9 values.

Keywords: Biological variation; Index of individuality; Proprotein convertase subtilisin/kexin type 9 (PCSK9); Reference change value.

MeSH terms

  • Cholesterol, LDL
  • Humans
  • Proprotein Convertase 9*
  • Receptors, LDL*
  • Subtilisins

Substances

  • Cholesterol, LDL
  • Receptors, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Subtilisins